Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051347 · ClinicalTrials.gov registry record · NA
Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
A NA study of Atopic Dermatitis and Psoriasis, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 943
- Enrollment target
- 1
- Study location
NCT03051347: Completed NA study of Atopic Dermatitis and Psoriasis, sponsored by Northwestern University.
NCT03051347 is a NA study of Atopic Dermatitis and Psoriasis that has completed, run by Northwestern University. The registered enrollment target is 943 participants, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (56% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03051347, a NA study of Atopic Dermatitis and Psoriasis, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 943 participants
- Enrollment target
- 1
- Study location
Study Summary
This is designated to validate patient-reported outcomes (PRO) measures in itch-specific pediatric skin conditions, such as atopic dermatitis, and examine the ability of a modified stigma instrument to assess the severity and type of stigma experienced in atopic dermatitis and other potentially stigmatizing conditions.
Conditions Studied
Interventions
- OTHER Itch Questionnaire and Interview
- OTHER Stigma Questionnaire and Interview
- OTHER Cognitive Interview and PROMIS Itch Questionnaire
Study Locations (1)
Illinois
- Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 943 participants |
| Start Date | 2016-09 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
What the finished NCT03051347 record still lists
NCT03051347 is an interventional study that assigns participants to a tested intervention. The registered 943 participants enrollment target is mid-sized for trials with a published cap, above the 603-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (56% higher).
The record links to 3 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Itch Questionnaire and Interview is the first listed.
NCT03051347 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03051347 about?
NCT03051347 is a clinical study titled "Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments". This is designated to validate patient-reported outcomes (PRO) measures in itch-specific pediatric skin conditions, such as atopic dermatitis, and examine the ability of a modified stigma instrument to assess the severity and type of stigma experienced in atopic dermatitis and other potentially stig...
What is the current status of trial NCT03051347?
This trial is currently completed. It is a NA study. The enrollment target is 943 participants. The study started on 2016-09. Estimated completion is 2020-06-30.
What conditions does trial NCT03051347 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Psoriasis, Ichthyosis.
What interventions are being tested in trial NCT03051347?
The interventions under investigation include: Itch Questionnaire and Interview (OTHER), Stigma Questionnaire and Interview (OTHER), Cognitive Interview and PROMIS Itch Questionnaire (OTHER).
Who is sponsoring clinical trial NCT03051347?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03051347 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03051347's enrollment target sits among peer trials
943 14th of 150 higher than 137 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
-
Topical Treatment for Atopic Dermatitis
RECRUITING · NA
-
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
COMPLETED · NA
-
A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis
COMPLETED · NA
-
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
COMPLETED · NA
-
Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia